Magaña ZL

Language: Spanish
References: 7
Page: 114-117
PDF size: 117.65 Kb.

REFERENCES

1. Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020; 348: 577387.

2. Chan KH, Lee CY. Treatment of neuromyelitis optica spectrum disorders. Int J Mol Sci. 2021; 22 (16): 8638.

3. Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021; 18 (1): 208.

4. Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021; 89 (6): 1088-1098.

5. Shi M, Chu F, Jin T, Zhu J. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD. CNS Neurosci Ther. 2022; 28 (7): 981-991.

6. Waliszewska-Prosól M, Chojdak-Lukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis optica spectrum disorder treatment-current and future prospects. Int J Mol Sci. 2021; 22 (6): 2801.

7. Holmoy T, Hoglund RA, Illes Z, Myhr KM, Torkildsen O. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol. 2021; 268 (12): 4522-4536.